Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Provention Bio Inc. is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals sector. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's current prosecution efforts are split between different specialized groups at the patent office.
The busiest examiner for this portfolio is GUSTILO, ESTELLA M, who is handling 1 pending office action. Since each of the 2 examiners holds 1 pending action, no single examiner dominates the company's current legal landscape. Practitioners must account for the distinct requirements of 2 separate art units when managing these filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| CHHAY, BONIRATH | 1 | 62.5% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691228 | Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691228 | Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691228 | Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes | GUSTILO, ESTELLA M | 1646 | §103§112Other | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18321964 | METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES | CHHAY, BONIRATH | 1645 | §103§112DP | Final Rejection | 50d | Pending | May 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProvention Bio Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Estella M Gustilo has the most, with 1 of Provention Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.